Abstract
The emergence of Omicron and Delta variants of SARS-CoV-2 has begun a number of discussions regarding breakthrough infection, waning immunity, need and timing for vaccine boosters and whether existing mRNA vaccines for the wildtype strain are adequate. Our work leverages a biosensor-based technique to evaluate the binding efficacy of SARS-CoV-2 S1 specific salivary antibodies to the Omicron and Delta variants using a cohort of mRNA vaccinated (n=109) and convalescent (n=19) subjects. We discovered a wide range of binding efficacies to the variant strains, with a mean reduction of 60.5%, 26.7%, and 14.7% in measurable signal to the Omicron strain and 13.4%, 2.4%, and −6.4% percent mean reduction to the Delta Variant for convalescent, Pfizer, and Moderna vaccinated groups respectively. This assay may be an important tool in determining susceptibility to infection or need for booster immunization as the pandemic evolves.
Key Points
AMPERIAL assay developed to quantify salivary SARS-CoV-2 S1 IgG antibodies to Omicron and Delta variants
There was a reduction in affinity to both Delta and Omicron Variants
The reduction in affinity was more pronounced to Omicron than for Delta Variants
There was a significant difference between IgG affinities in Individuals vaccinated with Pfizer versus Moderna Vaccines
Competing Interest Statement
D. Wong is consultant to Colgate-Palmolive, Mars Wrigley and GSK. D. Wong also have equity in Liquid Diagnostics and RNAmeTRIX. CS, MT are shareholders in Liquid Diagnostics LLC. MT is a shareholder of EZLife Bio Inc. MT is a paid consultant of Liquid Diagnostics LLC.
Funding Statement
This study was funded by Liquid Diagnostics LLC. DW is supported by U18 TR003778, U54 HL119893
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research protocol and consents were approved by the Western Internal Review Board (Study #1302611).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Funding sources: U18 TR003778, U54 HL119893 (to DTWW)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
